Orbeos (Atorvastatin)

Atorvastatin, the active ingredient in Orbeos, is a HMG‑CoA reductase inhibitor presented as a tablet for oral use. It lowers elevated cholesterol levels and reduces cardiovascular risk in adults with hyperlipidaemia. GNH USA supplies Orbeos as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Orbeos (atorvastatin) acts on lipid metabolism to manage dyslipidaemia and related cardiovascular conditions.

Hypercholesterolemia: lowers LDL‑cholesterol and total cholesterol levels. Prevention of cardiovascular events: reduces risk of myocardial infarction, stroke and related complications. Familial hypercholesterolemia: improves lipid profile in genetically predisposed patients. Secondary prevention of atherosclerotic disease: helps maintain target lipid levels after prior cardiovascular events.

Common Side Effects: - Muscle pain or weakness - Headache - Abdominal discomfort - Nausea - Constipation - Elevated liver enzymes

Serious or Rare Side Effects: - Rhabdomyolysis leading to renal failure - Severe hepatitis or liver injury - Allergic reactions such as rash or angioedema - Myopathy with marked CK elevation - Acute renal failure secondary to muscle breakdown - Stevens‑Johnson syndrome or toxic epidermal necrolysis

Before initiating therapy, consider patient‑specific factors and monitor appropriately. - Renal impairment: assess kidney function and adjust therapy if needed. - Hepatic disease: obtain baseline liver enzymes and monitor periodically. - Pregnancy: avoid use unless potential benefit justifies potential risk. - Drug interactions: review concomitant medications for statin‑related risks. - Grapefruit consumption: advise patients to limit intake as it may increase drug levels. - Store at ambient temperature: keep in original packaging, protect from moisture and direct sunlight.

Atorvastatin may interact with several medicines; careful assessment is required.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., clarithromycin, itraconazole): can markedly increase atorvastatin exposure. - Gemfibrozil: heightens risk of myopathy and rhabdomyolysis. - Cyclosporine: raises plasma concentrations, increasing toxicity risk. - Protease inhibitors (e.g., ritonavir): may cause severe statin accumulation.

Moderate Interactions (Monitor Closely): - Warfarin: may enhance anticoagulant effect, requiring INR monitoring. - Macrolide antibiotics (e.g., erythromycin): can modestly increase statin levels. - Antidiabetic agents: may affect glycaemic control, necessitating glucose monitoring. - Niacin: combined use raises likelihood of muscle toxicity.